New York, New York–(Newsfile Corp. – January 10, 2025) – WHY: The Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Caribou Biosciences, Inc. (NASDAQ: CRBU) between July 14, 2023 and July 16, 2024, both dates inclusive (the “Class Period”). If you want to serve as the lead plaintiff, you must move the Court no later than February 24, 2025.

WHATEVER: If you purchased Caribou securities during the Class Period you may be entitled to compensation free of any out-of-pocket fees or expenses through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Caribou class action, go to https://rosenlegal.com/submit-form/?case_id=11988 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for class action information. A class action lawsuit has been filed. If you want to serve as the lead plaintiff, you must move the Court no later than February 24, 2025. A lead plaintiff is a representative party acting on behalf of other class members in the conduct of litigation.

WHY ROSEN LAW: We encourage investors to select qualified advisors with a track record of success in leadership roles. Often, the companies issuing the notices do not have the same experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen who refer clients or partners to the law firms that actually litigate the cases. Be wise in choosing advice. The Rosen Law Firm represents investors worldwide, concentrating its practice in securities class actions and shareholder derivative litigation. The Rosen Law Firm achieved the largest securities class action settlement against a Chinese Company at that time. Rosen Law Firm is ranked No. 1 in the ISS Securities Class action (WA:) Services for the number of securities class action settlements in 2017. The company has been ranked in the top 4 every year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the company earned over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

CASE DETAILS: According to the lawsuit, throughout the Class Period, the defendants made false and misleading statements and/or failed to disclose that: (1) the defendants overstated the safety, efficacy, and durability of CB- 010 in relation to approved autologous CAR-T cell therapies for the treatment of patients. with r/r B-NHL and/or LBCL, as well as CB-010’s overall clinical results and commercial prospects; (2) Caribou has a significant risk that it will lack cash, liquidity, and/or other capital to fund its current business operations, including preclinical research activities related to the allogeneic CAR-NK platform; (3) the foregoing is likely to have a significant negative impact on Caribou’s business and operations; and (4) as a result, the defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damage.

To join the Caribou class action, go to https://rosenlegal.com/submit-form/?case_id=11988, call Phillip Kim, Esq. toll-free at 866-767-3653, or email [email protected] for class action information.

No Class Verified. Until a class is certified, you are not represented by counsel unless you hold one. You can choose the advice you want. You can also stay out of class and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent on serving as the lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook (NASDAQ:): https :// /www.facebook.com/rosenlawfirm/.

Attorney Advertising. The first results do not guarantee a similar result.

—————————–

To view the original version of this press release, please visit https://www.newsfilecorp.com/release/236786